Selected research
Industry Research
Spasmolytic Injections Industry Research Report 2026
Market perspective
The global Spasmolytic Injections market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Spasmolytic Injections market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Spasmolytic Injections market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Spasmolytic Injections market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Spasmolytic Injections include AdvaCare Pharma, Allergan, Baxter International, Boehringer Ingelheim, Chengdu Better Pharmaceutical, CNS Therapeutics, Huarun Shuanghe, Ipsen and Medytox, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Spasmolytic Injections market in terms of revenue (US$ million) and, where applicable, service volume (L), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/L) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Spasmolytic Injections.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Spasmolytic Injections Market by Company
AdvaCare Pharma
Allergan
Baxter International
Boehringer Ingelheim
Chengdu Better Pharmaceutical
CNS Therapeutics
Huarun Shuanghe
Ipsen
Medytox
Nanjing Hangsheng Pharmaceutical
Sun Pharmaceutical Industries
Wanbangde Pharmaceutical Group
Wuhan Renfu Pharmaceutical
Zydus Cadila
Lilly
Mylan
Sanofi
Teva Pharmaceuticals
Spasmolytic Injections Segment by Type
Papaverines
Anticholinergics
Calcium Channel Blockers
Others
Spasmolytic Injections Segment by Application
Hospital
Clinic
Spasmolytic Injections Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spasmolytic Injections market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Spasmolytic Injections and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spasmolytic Injections.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Spasmolytic Injections companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Papaverines
- Anticholinergics
- Calcium Channel Blockers
- Others
Applications
- Hospital
- Clinic
Companies covered
- AdvaCare Pharma
- Allergan
- Baxter International
- Boehringer Ingelheim
- Chengdu Better Pharmaceutical
- CNS Therapeutics
- Huarun Shuanghe
- Ipsen
- Medytox
- Nanjing Hangsheng Pharmaceutical
- Sun Pharmaceutical Industries
- Wanbangde Pharmaceutical Group
- Wuhan Renfu Pharmaceutical
- Zydus Cadila
- Lilly
- Mylan
- Sanofi
- Teva Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Spasmolytic Injections by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Papaverines
- 2.2.3 Anticholinergics
- 2.2.4 Calcium Channel Blockers
- 2.2.5 Others
- 2.3 Spasmolytic Injections by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.4 Assumptions and Limitations
3 Spasmolytic Injections Breakdown Data by Type
- 3.1 Global Spasmolytic Injections Historic Market Size by Type (2021-2026)
- 3.2 Global Spasmolytic Injections Forecasted Market Size by Type (2027-2032)
4 Spasmolytic Injections Breakdown Data by Application
- 4.1 Global Spasmolytic Injections Historic Market Size by Application (2021-2026)
- 4.2 Global Spasmolytic Injections Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Spasmolytic Injections Market Perspective (2021-2032)
- 5.2 Global Spasmolytic Injections Growth Trends by Region
- 5.2.1 Global Spasmolytic Injections Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Spasmolytic Injections Historic Market Size by Region (2021-2026)
- 5.2.3 Spasmolytic Injections Forecasted Market Size by Region (2027-2032)
- 5.3 Spasmolytic Injections Market Dynamics
- 5.3.1 Spasmolytic Injections Industry Trends
- 5.3.2 Spasmolytic Injections Market Drivers
- 5.3.3 Spasmolytic Injections Market Challenges
- 5.3.4 Spasmolytic Injections Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Spasmolytic Injections Players by Revenue
- 6.1.1 Global Top Spasmolytic Injections Players by Revenue (2021-2026)
- 6.1.2 Global Spasmolytic Injections Revenue Market Share by Players (2021-2026)
- 6.2 Global Spasmolytic Injections Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Spasmolytic Injections Head Office and Area Served
- 6.4 Global Spasmolytic Injections Players, Product Type & Application
- 6.5 Global Spasmolytic Injections Manufacturers Established Date
- 6.6 Global Spasmolytic Injections Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Spasmolytic Injections Market Size (2021-2032)
- 7.2 North America Spasmolytic Injections Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Spasmolytic Injections Market Size by Country (2021-2026)
- 7.4 North America Spasmolytic Injections Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Spasmolytic Injections Market Size (2021-2032)
- 8.2 Europe Spasmolytic Injections Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Spasmolytic Injections Market Size by Country (2021-2026)
- 8.4 Europe Spasmolytic Injections Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Spasmolytic Injections Market Size (2021-2032)
- 9.2 Asia-Pacific Spasmolytic Injections Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Spasmolytic Injections Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Spasmolytic Injections Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Spasmolytic Injections Market Size (2021-2032)
- 10.2 South America Spasmolytic Injections Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Spasmolytic Injections Market Size by Country (2021-2026)
- 10.4 South America Spasmolytic Injections Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Spasmolytic Injections Market Size (2021-2032)
- 11.2 Middle East & Africa Spasmolytic Injections Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Spasmolytic Injections Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Spasmolytic Injections Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AdvaCare Pharma
- 12.1.1 AdvaCare Pharma Company Information
- 12.1.2 AdvaCare Pharma Business Overview
- 12.1.3 AdvaCare Pharma Revenue in Spasmolytic Injections Business (2021-2026)
- 12.1.4 AdvaCare Pharma Spasmolytic Injections Product Portfolio
- 12.1.5 AdvaCare Pharma Recent Developments
- 12.2 Allergan
- 12.2.1 Allergan Company Information
- 12.2.2 Allergan Business Overview
- 12.2.3 Allergan Revenue in Spasmolytic Injections Business (2021-2026)
- 12.2.4 Allergan Spasmolytic Injections Product Portfolio
- 12.2.5 Allergan Recent Developments
- 12.3 Baxter International
- 12.3.1 Baxter International Company Information
- 12.3.2 Baxter International Business Overview
- 12.3.3 Baxter International Revenue in Spasmolytic Injections Business (2021-2026)
- 12.3.4 Baxter International Spasmolytic Injections Product Portfolio
- 12.3.5 Baxter International Recent Developments
- 12.4 Boehringer Ingelheim
- 12.4.1 Boehringer Ingelheim Company Information
- 12.4.2 Boehringer Ingelheim Business Overview
- 12.4.3 Boehringer Ingelheim Revenue in Spasmolytic Injections Business (2021-2026)
- 12.4.4 Boehringer Ingelheim Spasmolytic Injections Product Portfolio
- 12.4.5 Boehringer Ingelheim Recent Developments
- 12.5 Chengdu Better Pharmaceutical
- 12.5.1 Chengdu Better Pharmaceutical Company Information
- 12.5.2 Chengdu Better Pharmaceutical Business Overview
- 12.5.3 Chengdu Better Pharmaceutical Revenue in Spasmolytic Injections Business (2021-2026)
- 12.5.4 Chengdu Better Pharmaceutical Spasmolytic Injections Product Portfolio
- 12.5.5 Chengdu Better Pharmaceutical Recent Developments
- 12.6 CNS Therapeutics
- 12.6.1 CNS Therapeutics Company Information
- 12.6.2 CNS Therapeutics Business Overview
- 12.6.3 CNS Therapeutics Revenue in Spasmolytic Injections Business (2021-2026)
- 12.6.4 CNS Therapeutics Spasmolytic Injections Product Portfolio
- 12.6.5 CNS Therapeutics Recent Developments
- 12.7 Huarun Shuanghe
- 12.7.1 Huarun Shuanghe Company Information
- 12.7.2 Huarun Shuanghe Business Overview
- 12.7.3 Huarun Shuanghe Revenue in Spasmolytic Injections Business (2021-2026)
- 12.7.4 Huarun Shuanghe Spasmolytic Injections Product Portfolio
- 12.7.5 Huarun Shuanghe Recent Developments
- 12.8 Ipsen
- 12.8.1 Ipsen Company Information
- 12.8.2 Ipsen Business Overview
- 12.8.3 Ipsen Revenue in Spasmolytic Injections Business (2021-2026)
- 12.8.4 Ipsen Spasmolytic Injections Product Portfolio
- 12.8.5 Ipsen Recent Developments
- 12.9 Medytox
- 12.9.1 Medytox Company Information
- 12.9.2 Medytox Business Overview
- 12.9.3 Medytox Revenue in Spasmolytic Injections Business (2021-2026)
- 12.9.4 Medytox Spasmolytic Injections Product Portfolio
- 12.9.5 Medytox Recent Developments
- 12.10 Nanjing Hangsheng Pharmaceutical
- 12.10.1 Nanjing Hangsheng Pharmaceutical Company Information
- 12.10.2 Nanjing Hangsheng Pharmaceutical Business Overview
- 12.10.3 Nanjing Hangsheng Pharmaceutical Revenue in Spasmolytic Injections Business (2021-2026)
- 12.10.4 Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Product Portfolio
- 12.10.5 Nanjing Hangsheng Pharmaceutical Recent Developments
- 12.11 Sun Pharmaceutical Industries
- 12.11.1 Sun Pharmaceutical Industries Company Information
- 12.11.2 Sun Pharmaceutical Industries Business Overview
- 12.11.3 Sun Pharmaceutical Industries Revenue in Spasmolytic Injections Business (2021-2026)
- 12.11.4 Sun Pharmaceutical Industries Spasmolytic Injections Product Portfolio
- 12.11.5 Sun Pharmaceutical Industries Recent Developments
- 12.12 Wanbangde Pharmaceutical Group
- 12.12.1 Wanbangde Pharmaceutical Group Company Information
- 12.12.2 Wanbangde Pharmaceutical Group Business Overview
- 12.12.3 Wanbangde Pharmaceutical Group Revenue in Spasmolytic Injections Business (2021-2026)
- 12.12.4 Wanbangde Pharmaceutical Group Spasmolytic Injections Product Portfolio
- 12.12.5 Wanbangde Pharmaceutical Group Recent Developments
- 12.13 Wuhan Renfu Pharmaceutical
- 12.13.1 Wuhan Renfu Pharmaceutical Company Information
- 12.13.2 Wuhan Renfu Pharmaceutical Business Overview
- 12.13.3 Wuhan Renfu Pharmaceutical Revenue in Spasmolytic Injections Business (2021-2026)
- 12.13.4 Wuhan Renfu Pharmaceutical Spasmolytic Injections Product Portfolio
- 12.13.5 Wuhan Renfu Pharmaceutical Recent Developments
- 12.14 Zydus Cadila
- 12.14.1 Zydus Cadila Company Information
- 12.14.2 Zydus Cadila Business Overview
- 12.14.3 Zydus Cadila Revenue in Spasmolytic Injections Business (2021-2026)
- 12.14.4 Zydus Cadila Spasmolytic Injections Product Portfolio
- 12.14.5 Zydus Cadila Recent Developments
- 12.15 Lilly
- 12.15.1 Lilly Company Information
- 12.15.2 Lilly Business Overview
- 12.15.3 Lilly Revenue in Spasmolytic Injections Business (2021-2026)
- 12.15.4 Lilly Spasmolytic Injections Product Portfolio
- 12.15.5 Lilly Recent Developments
- 12.16 Mylan
- 12.16.1 Mylan Company Information
- 12.16.2 Mylan Business Overview
- 12.16.3 Mylan Revenue in Spasmolytic Injections Business (2021-2026)
- 12.16.4 Mylan Spasmolytic Injections Product Portfolio
- 12.16.5 Mylan Recent Developments
- 12.17 Sanofi
- 12.17.1 Sanofi Company Information
- 12.17.2 Sanofi Business Overview
- 12.17.3 Sanofi Revenue in Spasmolytic Injections Business (2021-2026)
- 12.17.4 Sanofi Spasmolytic Injections Product Portfolio
- 12.17.5 Sanofi Recent Developments
- 12.18 Teva Pharmaceuticals
- 12.18.1 Teva Pharmaceuticals Company Information
- 12.18.2 Teva Pharmaceuticals Business Overview
- 12.18.3 Teva Pharmaceuticals Revenue in Spasmolytic Injections Business (2021-2026)
- 12.18.4 Teva Pharmaceuticals Spasmolytic Injections Product Portfolio
- 12.18.5 Teva Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst